A New Frontier in Cancer Screening and Treatment
If liquid biopsy lives up to its potential, a paradigm shift in cancer detection is possible.
The nascent liquid biopsy market may expand rapidly in the next 5-10 years, and we think one area of expansion--early cancer detection--holds particular promise. We believe liquid biopsies (a noninvasive method of analyzing tumors using fluids such as blood) may induce a paradigm shift in when cancer is detected and then treated, enabling earlier-stage treatments, where survival rates are higher and treatment costs per patient are lower. In general, we see a host of incentives for end users, practitioners, and payers that could enable the widespread adoption of these tests, and we estimate the liquid biopsy market opportunity for early cancer detection could eventually exceed $70 billion in the U.S. alone, with global demand expanding that opportunity even further.
We cover three potential leaders in liquid biopsies for early cancer detection. Illumina (ILMN), through its pending acquisition of Grail, could become the first mover and long-term leader in pan-cancer biopsies (for multiple cancers in one test); while the shares recently traded moderately above our fair value estimate, we view them as the most reasonably priced of the three potential liquid biopsy leaders we cover. Exact Sciences (EXAS) could challenge Illumina/Grail in pan-cancer in about five years, but before then, it is likely to face competition from liquid biopsies in its legacy business--a stool-based test for colorectal cancer--that keeps us cautious about the stock. As the potential first mover in liquid biopsy for colorectal cancer, Guardant Health (GH) could threaten Exact Sciences and other traditional screening methods, such as colonoscopy, in that indication, but its stock appears rich, given the uncertainty around that opportunity and its other liquid biopsies in development.
Julie Utterback does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.